These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23934237)

  • 21. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
    Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States.
    Li P; Benson C; Geng Z; Seo S; Patel C; Doshi JA
    J Med Econ; 2023; 26(1):525-536. PubMed ID: 36961119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication adherence, healthcare costs and utilization associated with acne drugs in Medicaid enrollees with acne vulgaris.
    Tan X; Al-Dabagh A; Davis SA; Lin HC; Balkrishnan R; Chang J; Feldman SR
    Am J Clin Dermatol; 2013 Jun; 14(3):243-51. PubMed ID: 23572294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
    Rajagopalan K; Wade S; Meyer N; Loebel A
    Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder.
    Karve S; Markowitz M; Fu DJ; Lindenmayer JP; Wang CC; Candrilli SD; Alphs L
    Appl Health Econ Health Policy; 2014 Jun; 12(3):335-46. PubMed ID: 24756319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
    Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
    Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia.
    Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
    Value Health; 2009 Sep; 12(6):989-95. PubMed ID: 19402852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Medication Adherence and Healthcare Costs Among Patients Receiving the Low-Income Subsidy.
    Qiao Y; Steve Tsang CC; Hohmeier KC; Dougherty S; Hines L; Chiyaka ET; Wang J
    Value Health; 2020 Sep; 23(9):1210-1217. PubMed ID: 32940239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic adherence and emergency department utilization among patients with schizophrenia.
    Hardy M; Jackson C; Byrne J
    Schizophr Res; 2018 Nov; 201():347-351. PubMed ID: 29895413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
    Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
    Jiang Y; Ni W
    Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of treatment-related discussions on healthcare resource use and costs among patients with severe mental illness.
    Forma F; Koep E; White J; Belland A; Waters H; Martin C
    Curr Med Res Opin; 2021 Oct; 37(10):1799-1809. PubMed ID: 34139902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics.
    Lang K; Meyers JL; Korn JR; Lee S; Sikirica M; Crivera C; Dirani R; Menzin J
    Psychiatr Serv; 2010 Dec; 61(12):1239-47. PubMed ID: 21123409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.